A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation study designed to characterize the safety,
tolerability, efficacy, and pharmacokinetics of GNKG168 in patients with B-CLL that has
relapsed or is refractory to all prior standard therapy, or for which no standard therapy
exists.